Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States.
It is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata.
The company is headquartered in Dallas, Texas.